Merlin C Thomas
Overview
Explore the profile of Merlin C Thomas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
168
Citations
6210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chhabra K, Shoemaker R, Herath C, Thomas M, Filipeanu C, Lazartigues E
Physiol Rev
. 2025 Feb;
PMID: 39918873
Angiotensin Converting Enzyme 2 (ACE2) was discovered 25 years ago as a negative regulator of renin-angiotensin system, opposing the effects of angiotensin-II. Beyond its well-demonstrated roles in cardiovascular regulation and...
2.
Thomas M, Cooper M
Nat Rev Nephrol
. 2024 Jul;
20(10):637-638.
PMID: 39075285
No abstract available.
3.
Hadjadj S, Cooper M, Steubl D, Petrini M, Hantel S, Mattheus M, et al.
Kidney Med
. 2024 Feb;
6(3):100783.
PMID: 38419787
Rationale & Objective: Kidney function progressively declines in most patients with type 2 diabetes (T2DM). Many develop progressive chronic kidney disease (CKD), but some experience a more rapid decline, with...
4.
Thomas M, Neuen B, Twigg S, Cooper M, Badve S
Endocr Connect
. 2023 May;
12(8).
PMID: 37159343
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have recently emerged as an effective means to protect kidney function in people with type 2 diabetes and chronic kidney disease (CKD). In this review,...
5.
Hanssen N, Tikellis C, Pickering R, Dragoljevic D, Lee M, Block T, et al.
Biomed Pharmacother
. 2023 Mar;
158:114211.
PMID: 36916437
Methylglyoxal (MGO) is a reactive glucose metabolite linked to diabetic cardiovascular disease (CVD). MGO levels surge during intermittent hyperglycemia. We hypothesize that these MGO spikes contribute to atherosclerosis, and that...
6.
Thomas M, Coughlan M, Cooper M
Cell Metab
. 2023 Feb;
35(2):253-273.
PMID: 36754019
Recent clinical trials in people with type 2 diabetes have demonstrated beneficial actions on heart and kidney outcomes following treatment with GLP-1RAs. In part, these actions are consistent with improved...
7.
Khurana I, Kaipananickal H, Maxwell S, Birkelund S, Syreeni A, Forsblom C, et al.
J Clin Invest
. 2023 Jan;
133(4).
PMID: 36633903
Diabetic nephropathy (DN) is a polygenic disorder with few risk variants showing robust replication in large-scale genome-wide association studies. To understand the role of DNA methylation, it is important to...
8.
Tikellis C, Robinson G, Rosado C, Batu D, Zuniga-Gutierrez M, Pickering R, et al.
Antioxidants (Basel)
. 2022 May;
11(5).
PMID: 35624851
Circulating levels of soluble ACE2 are increased by diabetes. Although this increase is associated with the presence and severity of cardiovascular disease, the specific role of soluble ACE2 in atherogenesis...
9.
Thomas M
Adv Chronic Kidney Dis
. 2021 Dec;
28(4):282-289.
PMID: 34922684
The pathobiology of diabetic kidney disease (DKD) involves an interplay between all the many different cell types that exist within the kidney and their shared and cumulative dysfunction in response...
10.
Venkatesh N, Astbury N, Thomas M, Rosado C, Pappas E, Krishnamurthy B, et al.
Diabet Med
. 2021 May;
38(11):e14608.
PMID: 34043837
Aims: Aim of this study is to report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, responsible for coronavirus disease 2019 (COVID-19), as a possible cause for type 1 diabetes...